Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | (36813328) | ||||||||||||
Authors | Kwapisz D, Verret B, Garcia C, André F | ||||||||||||
Title | Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRIP1 T997fs | breast lobular carcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in a sustained metabolic response and a decrease in the cancer antigen markers CA 27-29 and CA 15-3 after 8 months in a patient with recurrent ER/PR-positive, ERBB2 (HER2)-negative invasive lobular breast carcinoma harboring a germline BRIP1 T997fs, who remained on treatment (PMID: 36813328). | 36813328 |